Supernus Pharmaceuticals Inc (SUPN)
Liquidity ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 2.35 | 2.20 | 1.91 | 1.73 | 1.70 | 1.56 | 1.68 | 1.21 | 1.07 | 0.91 | 0.85 | 2.00 | 1.91 | 2.85 | 2.26 | 2.43 | 2.57 | 1.84 | 2.07 | 3.31 |
| Quick ratio | 2.04 | 1.88 | 1.62 | 1.42 | 1.38 | 1.19 | 1.14 | 0.51 | 0.91 | 0.77 | 0.71 | 1.61 | 1.55 | 2.46 | 1.93 | 2.15 | 2.30 | 1.62 | 1.86 | 3.09 |
| Cash ratio | 1.55 | 1.38 | 1.12 | 0.95 | 0.88 | 0.70 | 0.60 | 0.31 | 0.67 | 0.54 | 0.49 | 1.10 | 1.08 | 1.89 | 1.45 | 1.62 | 1.72 | 1.17 | 1.39 | 2.38 |
Supernus Pharmaceuticals Inc's liquidity ratios, namely the current ratio, quick ratio, and cash ratio, provide insight into the company's ability to meet its short-term obligations.
- Current Ratio: This ratio indicates Supernus Pharmaceuticals Inc's ability to pay its short-term liabilities with its current assets. The company's current ratio fluctuated over the analyzed period, ranging from a high of 3.31 in March 2020 to a low of 0.85 in June 2022. A general upward trend can be observed from December 2021 to September 2024, indicating an overall improvement in liquidity.
- Quick Ratio: The quick ratio measures the company's ability to cover its current liabilities with its most liquid assets, excluding inventory. Supernus Pharmaceuticals Inc's quick ratio also experienced fluctuations during the period, with values ranging from 0.51 in March 2023 to 2.46 in September 2021. The ratios generally followed a similar trend to the current ratio, showing an improvement from December 2021 to September 2024.
- Cash Ratio: This ratio assesses Supernus Pharmaceuticals Inc's ability to cover its current liabilities with cash and cash equivalents alone. The cash ratio fluctuated over time, with values ranging from 0.31 in March 2023 to 2.38 in March 2020. While there were fluctuations, there was an overall improvement in liquidity from December 2023 to December 2024.
In summary, Supernus Pharmaceuticals Inc's liquidity ratios show fluctuations but overall improvement in liquidity from December 2021 to September 2024. This indicates the company's ability to meet its short-term obligations and suggests a more stable financial position in terms of liquidity over the analyzed period.
Additional liquidity measure
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash conversion cycle | days | 123.50 | 152.17 | 162.61 | 160.39 | 172.39 | 153.35 | 146.88 | 139.74 | 153.00 | 142.07 | 134.18 | 157.78 | 170.20 | 144.25 | 148.07 | 142.51 | 160.99 | 155.90 | 167.46 | 151.54 |
The cash conversion cycle measures the time it takes for a company to convert its investments in inventory and other resources into cash flows from sales. Analyzing the data provided for Supernus Pharmaceuticals Inc from March 31, 2020, to December 31, 2024, we can observe fluctuations in the cash conversion cycle.
The cash conversion cycle for Supernus Pharmaceuticals Inc fluctuated over the periods analyzed, ranging from a low of 123.50 days on December 31, 2024, to a high of 172.39 days on December 31, 2023. Generally, a lower cash conversion cycle indicates that the company is more efficient in managing its working capital, indicating a quicker cycle of converting resources into cash.
Looking at specific points in time, the company experienced its lowest cash conversion cycle of 123.50 days on December 31, 2024, reflecting potential improvements in working capital management. Conversely, the highest cash conversion cycle of 172.39 days on December 31, 2023, may indicate challenges in efficiently converting investments into cash flows from sales.
Overall, observing the trend of the cash conversion cycle over time can provide insights into Supernus Pharmaceuticals Inc's ability to effectively manage its working capital and potentially identify areas for improvement in operational efficiency.